Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Seattle Genetics Inc (SGEN)

Seattle Genetics Inc (SGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,441,202
  • Shares Outstanding, K 172,260
  • Annual Sales, $ 916,710 K
  • Annual Income, $ -158,650 K
  • 60-Month Beta 1.42
  • Price/Sales 21.89
  • Price/Cash Flow N/A
  • Price/Book 10.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.77
  • Number of Estimates 9
  • High Estimate -0.65
  • Low Estimate -0.95
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -140.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
90.57 +34.56%
on 03/16/20
128.00 -4.79%
on 04/07/20
+7.00 (+6.09%)
since 03/06/20
3-Month
90.57 +34.56%
on 03/16/20
128.00 -4.79%
on 04/07/20
+10.55 (+9.48%)
since 01/07/20
52-Week
62.90 +93.75%
on 05/15/19
128.00 -4.79%
on 04/07/20
+42.50 (+53.55%)
since 04/05/19

Most Recent Stories

More News
Seattle Genetics Issue Update on Padcev Label Expansion Study

Seattle Genetics (SGEN) may receive an expedited approval pathway for Padcev combo to treat patients with locally advanced/metastatic urothelial cancer in the first-line setting in the United States.

REGN : 502.56 (-0.34%)
MRK : 78.56 (-2.18%)
ACOR : 0.9290 (-0.11%)
SGEN : 121.87 (-2.09%)
Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer

Seattle Genetics, Inc. (Nasdaq:SGEN) today provided an update on the phase 1b/2 multicohort EV-103 trial (also known as KEYNOTE-869) of PADCEV(TM) (enfortumab vedotin-ejfv) in combination with anti-PD-1...

SGEN : 121.87 (-2.09%)
SmarTrend Watching for Potential Pullback in Shares of Seattle Genetics After 3.26% Gain

Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $100.01 to a high of $106.57. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high...

SGEN : 121.87 (-2.09%)
Seattle Genetics Has Returned 10.0% Since SmarTrend Recommendation (SGEN)

SmarTrend identified a Downtrend for Seattle Genetics (NASDAQ:SGEN) on February 27th, 2020 at $109.69. In approximately 3 weeks, Seattle Genetics has returned 10.00% as of today's recent price of $98.72....

SGEN : 121.87 (-2.09%)
SmarTrend Watching for Potential Rebound in Shares of Seattle Genetics After 2.54% Loss

Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $103.56 to a high of $108.81. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of...

SGEN : 121.87 (-2.09%)
Seattle Genetics Inc - Financial & Strategic SWOT Analysis Review, 2020 - ResearchAndMarkets.com

The "Seattle Genetics Inc (SGEN) - Financial and Strategic SWOT Analysis Review" swot analysis has been added to ResearchAndMarkets.com's offering.

SGEN : 121.87 (-2.09%)
Seattle Genetics to Webcast Virtual Fireside Chat at Barclays Global Healthcare Conference

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay Siegall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on...

SGEN : 121.87 (-2.09%)
Why Is Seattle Genetics (SGEN) Down 3.2% Since Last Earnings Report?

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SGEN : 121.87 (-2.09%)
Seattle Genetics Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the cancellation of the Company's presentation and webcast at the Cowen 40th Annual Healthcare Conference on Tuesday, previously scheduled to take place...

SGEN : 121.87 (-2.09%)
Global Advances in Breast Cancer Detection Creating $5.13 Billion Opportunity

Globally, breast cancer effects 2.1 million women every year. In 2018 alone, it was the cause of nearly 627,000 deaths, according to the World Health Organization, accounting for 15% of all cancer deaths...

IZO.CN : 0.180 (unch)
IZOZF : 0.1179 (+7.08%)
NDRA : 0.6940 (+6.10%)
BSX : 34.82 (+5.90%)
SGEN : 121.87 (-2.09%)
PBYI : 7.20 (-6.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade SGEN with:

Business Summary

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability...

See More

Key Turning Points

2nd Resistance Point 128.88
1st Resistance Point 126.68
Last Price 121.87
1st Support Level 120.35
2nd Support Level 116.22

See More

52-Week High 128.00
Last Price 121.87
Fibonacci 61.8% 103.13
Fibonacci 50% 95.45
Fibonacci 38.2% 87.77
52-Week Low 62.90

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar